U of MN researchers find genetic variations may predict treatment responses for myeloma

Researchers from The Cancer Center at the University of Minnesota have demonstrated that variations in genes may determine the outcome and toxicity of treatments for myeloma cancer patients. The findings support thinking that physicians may optimize care by adjusting treatment according to a patient's specific genetic condition. The findings will be presented September 15, 2003 at the American Association for Cancer Research (AACR)-sponsored specialty meeting on "SNPs, Haplotype, and Cancer: Application in Molecular Epidemiology."

Although chemotherapy drugs can be effective against myeloma in many patients, they can be less effective or even lethal in others. By determining a patient's toxic susceptibility to drugs through analysis of specific genetic variances, or single nucleotide polymorhphisms (SNPs), in genes known to promote myeloma growth, clinicians can adjust dosage levels or choose alternate, safer drugs to benefit the patient.

Led by Brian Van Ness, Ph.D., professor of genetics and a member of The Cancer Center, researchers analyzed patient samples from an Eastern Cooperative Oncology Group Study on myeloma chemotherapy treatments for 700 patients between 1987-1994. For this particular investigation, researchers examined 400 patient DNA samples for SNPs in genes that promote myeloma growth. Those patients with the SNPs that result in low production of the growth factor, generally had better outcomes to the chemotherapy and increased survival times.

"These data confirm that our research on genetic variances and their effect on treatment outcome is headed in the right direction," said Van Ness. "This important first step means we can start developing clinical trials based on genetic conditions that can lead to more effective treatments and help to evaluate new, targeted therapies."

Myeloma is a cancer of plasma cells, which are antibody-producing cells normally present in the bone marrow. More than 1,000 new cases or

Contact: Warren Froelich
American Association for Cancer Research

Page: 1 2

Related biology news :

1. Belgian researchers explore revolutionary approach to angiogenesis
2. Award winning researchers reveal potential new role for Glivec
3. $7.5 Million grant to Yale researchers for role of viruses in cancer
4. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
5. Joslin researchers clarify mechanisms for beta-cell formation
6. Virginia Tech researchers to release findings on Smith River Project
7. Molecular motor myosin VI moves hand over hand, researchers say
8. ASU researchers demonstrate new technique that improves the power of atomic force micrscopy
9. Emory researchers map structure of anti-cancer molecule
10. Leukemia stem cells identified by Stanford researchers
11. EURYI Award given for the first time to 25 young European researchers

Post Your Comments:

(Date:9/8/2019)... LA JOLLA, Calif. (PRWEB) , ... September 06, ... ... and the Board of Directors of Nanosens Innovations have each authorized the respective ... would become a subsidiary of Cardea, with the Nanosens brand representing a series ...
(Date:8/27/2019)... (PRWEB) , ... August 26, 2019 , ... Shoreline ... to the strain level, has hired Bill McKenzie as its CEO and Karen Woodward ... to help Shoreline Biome meet growing demand for its products and expand the company’s ...
(Date:8/25/2019)... ... 2019 , ... BioInformatics, part of Science and Medicine Group, ... helps connect companies with a network of thousands of life science and medical ... is moving faster than ever, and we have built a qualitative offering to ...
Breaking Biology News(10 mins):
(Date:8/23/2019)... ... August 22, 2019 , ... ... modalities and is scheduled to broadcast 4Q/2019. Check your local listings for more ... patches for generic drug delivery. Focusing on therapeutics for children and the elderly, ...
(Date:8/7/2019)... Ohio (PRWEB) , ... August 07, 2019 , ... Locus ... a breakthrough line of soil amendments (soil “probiotics”), including Rhizolizer ® , which ... a year—the largest impact any approach has offered to date. Results from the treatment ...
(Date:8/4/2019)... ... ... Cirtec Medical Corporation, a strategic outsourcing partner for complex medical devices, including ... a 30,000 sq. ft. manufacturing facility in the Coyol free zone, located in ... is expected to be fully operational by the end of the year, will be ...
(Date:7/19/2019)... ... 18, 2019 , ... World renowned two-time Everest summiter Ravichandran ... California-based charity Coalition Duchenne for its 9th Annual Expedition Mt. Kinabalu in Sabah, ... for Duchenne muscular dystrophy and was founded by Sabahan Catherine Jayasuriya. , ...
Breaking Biology Technology:
Cached News: